The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index; 22 of the 37 sources its claims cite were checked for support.
Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis
Open accessAbstract
Treatment-resistant depression (TRD) remains a major clinical challenge. Intranasal esketamine, used adjunctively with an oral antidepressant, has been evaluated in randomized trials, but uncertainty persists regarding the magnitude and consistency of benefit, durability, and key harms. This systematic review and meta-analysis included randomized controlled trials comparing intranasal esketamine plus an oral antidepressant versus placebo nasal spray plus the same oral antidepressant in TRD. Acute induction (≈4 weeks) and maintenance randomized-withdrawal phases were analyzed separately. Depression outcomes were assessed primarily using the Montgomery–Åsberg Depression Rating Scale (MADRS), and functional outcomes using the Sheehan Disability Scale (SDS). Two reviewers independently screened studies, extracted data, and assessed risk of bias using RoB 2.0. Random-effects models pooled mean differences (MD) for continuous outcomes, risk ratios (RR) for binary outcomes, and hazard ratios (HR) for relapse prevention. Certainty of evidence was rated using GRADE. From 1,518 records, nine reports representing six unique RCTs (1,836 participants) were included. Four acute induction RCTs (n=937) showed greater symptom reduction at day 28 with esketamine (MADRS MD −2.99, 95% CI −5.10 to −0.89; I²=48.5%). Rapid improvement was evident by day 2 (MD −3.25, 95% CI −4.65 to −1.85). Esketamine increased day-28 response (RR 1.44, 95% CI 1.20–1.74) and remission (RR 1.52, 95% CI 1.20–1.92), corresponding to approximately +154 responders and +106 remitters per 1,000 patients, respectively, based on pooled control risks. Functioning improved (SDS MD −1.70, 95% CI −2.61 to −0.79). Two maintenance randomized-withdrawal RCTs (n=899) demonstrated reduced relapse risk with continued esketamine (HR 0.51, 95% CI 0.42–0.62; I²=0%). In acute induction, esketamine increased any treatment-emergent adverse event (TEAE) (RR 1.37, 95% CI 1.25–1.50) and discontinuation due to adverse events (RR 2.68, 95% CI 1.35–5.29), with notable increases in dissociation (RR 7.33, 95% CI 4.49–11.98) and blood pressure increased events (RR 3.96, 95% CI 2.24–7.01). Maintenance TEAE rates were similar between groups (RR 1.07, 95% CI 0.99–1.17). Intranasal esketamine plus an oral antidepressant provides rapid, modest acute improvement and reduces relapse risk during maintenance among stabilized responders/remitters, but increases acute adverse events, supporting use within supervised care and individualized benefit–risk assessment.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis of six RCTs (1,836 participants) found that adjunctive intranasal esketamine plus an oral antidepressant produced rapid but modest acute symptom and functional improvement and reduced relapse risk in stabilized responders/remitters, while increasing acute adverse events. The authors conclude the benefit–harm profile supports use within supervised care and individualized benefit–risk assessment.
Key findings
- Acute induction (4 RCTs, n=937): esketamine reduced day-28 MADRS change (MD −2.99, 95% CI −5.10 to −0.89; I²=48.5%) and day-2 MADRS change (MD −3.25, 95% CI −4.65 to −1.85), increased response (RR 1.44, 95% CI 1.20–1.74) and remission (RR 1.52, 95% CI 1.20–1.92), improved SDS (MD −1.70, 95% CI −2.61 to −0.79), and increased CGI-I response (RR 1.33, 95% CI 1.16–1.53); absolute increases were +154 responders and +106 remitters per 1,000.
- Maintenance randomized-withdrawal (2 RCTs, n=899): continued esketamine reduced relapse risk (HR 0.51, 95% CI 0.42–0.62; I²=0%); trial relapse proportions were 25.9% vs 44.0% and 22.1% vs 39.5%, with an absolute risk reduction of 216 per 1,000 using an assumed control relapse risk of 440 per 1,000.
- Acute safety: any TEAE RR 1.37 (95% CI 1.25–1.50), discontinuation due to AE RR 2.68 (95% CI 1.35–5.29), dissociation RR 7.33 (95% CI 4.49–11.98), and blood pressure increased RR 3.96 (95% CI 2.24–7.01); maintenance any TEAE RR 1.07 (95% CI 0.99–1.17) and any-cause discontinuation RR 0.53 (95% CI 0.38–0.75).
- GRADE certainty was moderate for MADRS change at day 28, remission, SDS change, relapse prevention, and discontinuation due to AE, and high for response, day-2 MADRS change, dissociation, and blood pressure increased events.
Methods
- Systematic review and meta-analysis of randomized controlled trials comparing intranasal esketamine plus an oral antidepressant versus placebo nasal spray plus the same oral antidepressant in treatment-resistant depression; acute induction and maintenance randomized-withdrawal phases were analyzed separately.
- Searched PubMed/MEDLINE, Embase, Cochrane Library, PsycINFO, ClinicalTrials.gov, and WHO ICTRP to December 2025; from 1,518 records, included 9 reports representing 6 unique RCTs (1,836 participants).
- Two reviewers independently screened, extracted data, and assessed risk of bias with RoB 2.0; random-effects inverse-variance meta-analyses pooled MDs for continuous outcomes, RRs for binary outcomes, and HRs for relapse prevention, with sensitivity analyses, Bayesian meta-analysis, trial sequential analysis, and GRADE.
Limitations
- Stated in the paper: the protocol was not prospectively registered; several acute trials had “some concerns” due to potential functional unblinding and missing outcome data; some outcomes were informed by only 2–3 trials, limiting precision and publication-bias assessment; backbone-specific efficacy/safety could not be compared; induction trials largely ended at 4 weeks and maintenance used enriched randomized-withdrawal designs; older adults and medically complex populations remain understudied.
- Evident from the text: only two maintenance trials contributed to relapse prevention, precluding meaningful small-study or publication-bias assessment; the day-28 MADRS prediction interval included the null (−6.59 to +0.60), and the older-adult trial showed a near-null effect with borderline subgroup interaction (p=0.055), indicating possible heterogeneity and uncertain benefit in some settings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
12 Valid · 0 Not valid · 4 Not checked · 102 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Our findings are concordant with the direction and general magnitude of effect reported in pivotal trials of adjunctive intranasal esketamine in TRD and the relapse-prevention study (18–23)”
§ Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis > Discussion > Relation to the existing evidence base
What the sources say
- Partly supportedcites [18] Daly, 2018, Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial, JAMA Psychiatry sourceExperimental — accuracy not yet measured
The Abstract reports a placebo-adjusted reduction in depression scores with adjunctive intranasal esketamine in treatment-resistant depression, supporting the claimed direction and providing an effect magnitude. But the Conclusions describe this as an early study supporting larger trials, with a phase 3 study still under way; this source is not itself a pivotal or relapse-prevention trial. (LLM, conf=0.82)
- Supportedcites [19] Popova, 2019, Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study (TRANSFORM-2), Am J Psychiatry source
This source is an adjunctive intranasal esketamine trial in treatment-resistant depression, so it supports the pivotal-trial part of the grouped citation. The Results report greater improvement with esketamine plus a newly initiated antidepressant than with antidepressant plus placebo, and give a day-28 effect size of 0.30. The citing authors’ comparison with their own findings is not independently assessable from this source; the separate relapse-prevention study is not attributed to this trial alone. (LLM, conf=0.90)
- Supportedcites [20] Fedgchin, 2019, Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1), Int J Neuropsychopharmacol source
The Discussion reports day-28 treatment differences of −3.2 and −4.1 MADRS points, numerically favoring adjunctive esketamine over antidepressant plus placebo. This paper is one of the TRD trials cited for the direction and general magnitude of effect; it does not claim statistical significance for the 84-mg group. The relapse-prevention study is separately cited in the sentence. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [21] Ochs-Ross, 2020, Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression—TRANSFORM-3, Am J Geriatr Psychiatry source
- Supportedcites [22] Daly, 2019, Esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial (SUSTAIN-1), JAMA Psychiatry source
The Efficacy Results report that continued intranasal esketamine plus an oral antidepressant delayed relapse compared with antidepressant plus placebo in patients with treatment-resistant depression, with hazard ratios of 0.49 for stable remission and 0.30 for stable response. This supports the cited paper’s role as the relapse-prevention study and establishes the direction and magnitude of its reported effect; the comparison with the citing authors’ findings is their own assessment. (LLM, conf=0.90)
- Supportedcites [23] Chen, 2023, Efficacy and safety of flexibly dosed esketamine nasal spray plus a newly initiated oral antidepressant in adult patients with treatment-resistant depression: a randomized, double-blind, multicenter, active-controlled study conducted in China and USA, Neuropsychiatr Dis Treat source
The Results > Efficacy section (page unavailable) reports MADRS differences favoring adjunctive esketamine by 2.0 points at Day 28 and 3.3 points at 24 hours, supporting the claimed direction and providing the effect magnitude for this acute-treatment trial. The Day 28 difference was not statistically significant. The separately mentioned relapse-prevention study is not attributed specifically to this source in the multi-citation sentence. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Functional outcomes favored esketamine, with greater improvement in SDS total score at day 28 (MD −1.70, 95% CI −2.61 to −0.79; I²=0%)”
§ Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis > Results > Efficacy (acute induction)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Using an assumed control relapse risk of 440 per 1,000 over 6–12 months, the estimated relapse risk with continued esketamine was 224 per 1,000 (absolute risk reduction 216 per 1,000; moderate certainty)”
§ Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis > Results > Maintenance/relapse prevention
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Rapid antidepressant effects were also observed by day 2 (MADRS change: MD −3.25, 95% CI −4.65 to −1.85; I²=3.0%; 95% prediction interval −4.74 to −1.77)”
§ Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis > Results > Efficacy (acute induction)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Continuing esketamine plus oral antidepressant significantly reduced the hazard of relapse compared with switching to placebo nasal spray plus oral antidepressant (random-effects: HR 0.51, 95% CI 0.42–0.62; p<0.001; I²=0%, τ²=0)”
§ Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis > Results > Maintenance/relapse prevention
plainstates a causen = 899- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
69 more claims
Create a free account to see all 118 claims and every source verdict.
- Probably not a substantial claim. 19
- It may state two separate claims as one. 32
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis > Results
“Trial E (2020) (25) | RW, double-blind maintenance after open-label induction/stabilization”
§ Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis > References
“Wajs E Aluisio L Holder R Daly EJ Lane R Lim P. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis > Results > Study characteristics
“Esketamine dosing was flexible (56/84 mg) in three acute trials, one trial used a predominantly fixed 84 mg schedule, and the older-adult trial typically started at 28 mg with protocol-guided titration”
§ Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis > Results
“Trial D (2020) (21) | Double-blind, parallel-group; acute induction | Older adults ≥65; ≥2 failed AD trials (current episode) | 69/69 | 68.3 | 58 | 36.9 | Duloxetine/escitalopram/sertraline/venlafaxine XR | Start 28 mg; flexible 28/56/84 mg twice weekly × 4 weeks”
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“Heterogeneity was summarized with I², t ², and Cochran ’ s Q, and 95% prediction intervals were reported where appropriate (39 – 41).”
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“For outcomes supported by very few studies (e.g., maintenance relapse prevention with two randomized-withdrawal trials), formal publication-bias testing was not performed due to lack of interpretability (50 – 52).”
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Heterogeneity was summarized with I², t ², and Cochran ’ s Q, and 95% prediction intervals were reported where appropriate (39 – 41).”
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099
Research works printed but not linked: 5
- 2010, Practice guideline for the treatment of patients with major depressive disorder
- 2019, Spravato (esketamine) nasal spray, CIII
- HJ, 2013, GRADE handbook for grading quality of evidence and strength of recommendations
- H, 2022, Cochrane Handbook for Systematic Reviews of Interventions Version 6.3
- 2024, R: A language and environment for statistical computing
Cited by
Zhang, M., He, E., Xiong, Y., Xiong, A., Peng, X., Wang, Y., Gu, Y., Wu, J., & Liang, P. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.71545
“Intranasal administration, while effective in acute settings [86], introduces challenges related to patient acceptability and long-term adherence.”
Metadata
- Authors
- Xie, J., Pu, C., & Sun, M.
- Affiliations
- Beijing University of Chinese Medicine (CN)
- Corresponding author
- Xie, Jingqiang
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2026-07-03
- Volume
- 17
- Pages
- 1774549-1774549
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC13375723
- OpenAlex
- W7167284368
- Semantic Scholar
- 27551fc730b1a4cf6830ce2e6555974991b9e1a7
- Cited by
- 1
- References
- 45
- Citations by year
- 2026: 1
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- esketamine, intranasal esketamine, treatment-resistant depression, adjunctive antidepressant therapy, relapse prevention, maintenance therapy, remission, functional disability, treatment-emergent adverse events, NMDA receptor antagonists, risk of bias, quality of evidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis. https://app.cochat.ai/papers/10.3389/fpsyt.2026.1774549
- The paper
- Xie, J., Pu, C., & Sun, M. (2026). Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2026.1774549
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.